Home   Categories   Grid

Subscribe Now

Coronavirus vaccine being created by Cambridge laboratory may offer best hope in tackling epidemic

Coronavirus vaccine being created by Cambridge laboratory may offer best hope in tackling epidemic

Coronavirus vaccine being created by Cambridge laboratory may offer best hope in tackling epidemic

07 February 2020

Professor Jonathan Heeney, CEO of DIOSVax, says with the right resources it can move quickly.


Reversing osteoarthritis: Mogrify secures $1.1m to assess cartilage regeneration therapy

Reversing osteoarthritis: Mogrify secures $1.1m to assess cartilage regeneration therapy

Reversing osteoarthritis: Mogrify secures $1.1m to assess cartilage regeneration therapy

05 February 2020

The Cambridge Science Park-based company is transforming cell therapies with its technology.


Abcam acquires gene-editing platform from US biotech Applied StemCell

Abcam acquires gene-editing platform from US biotech Applied StemCell

Abcam acquires gene-editing platform from US biotech Applied StemCell

05 February 2020

The Cambridge Biomedical Campus company has also purchased the oncology product portfolio.


How Turbine is bringing the winds of change to drug discovery

How Turbine is bringing the winds of change to drug discovery

How Turbine is bringing the winds of change to drug discovery

01 February 2020

It has created a Simulated Cell platform capable of simulating hundreds of millions of experiments.


AstraZeneca launches $1bn strategy to be zero carbon by 2025 - and it will plant an AZ Forest with 50 million trees

AstraZeneca launches $1bn strategy to be zero carbon by 2025 - and it will plant an AZ Forest with 50 million trees

AstraZeneca launches $1bn strategy to be zero carbon by 2025 - and it will plant an AZ Forest with 50 million trees

30 January 2020

The Cambridge-based biopharmaceutical aims for its supply chain to be carbon negative by 2030.


Stemnovate offers ‘unique’ multi-organ drug screening on reprogrammed human cells

Stemnovate offers ‘unique’ multi-organ drug screening on reprogrammed human cells

Stemnovate offers ‘unique’ multi-organ drug screening on reprogrammed human cells

18 January 2020

The Babraham Research Campus company provides an alternative to animal testing using liver, heart, brain, pancreas and immunological cells.


Cancer Research UK to fund clinical trial of Bicycle Therapeutics immuno-oncology candidate

Cancer Research UK to fund clinical trial of Bicycle Therapeutics immuno-oncology candidate

Cancer Research UK to fund clinical trial of Bicycle Therapeutics immuno-oncology candidate

15 January 2020

CRUK suggests the molecule could offer improved anti-tumor activity with fewer side effects compared to antibody-based approaches.


Cambridge Design Partnership works on new robotic surgery system with Titan Medical

Cambridge Design Partnership works on new robotic surgery system with Titan Medical

Cambridge Design Partnership works on new robotic surgery system with Titan Medical

15 January 2020

A rival to CMR Surgical’s Versius, the SPORT system is focused on using single incisions.


Illumina’s $1.2bn acquisition of Pacific Biosciences called off

Illumina’s $1.2bn acquisition of Pacific Biosciences called off

Illumina’s $1.2bn acquisition of Pacific Biosciences called off

10 January 2020

The sequencing companies were left frustrated by time taken for regulatory approval.


Astex Pharmaceuticals and Taiho Pharmaceutical sign cancer drug deal with Merck that could be worth $2.5billion

Astex Pharmaceuticals and Taiho Pharmaceutical sign cancer drug deal with Merck that could be worth $2.5billion

Astex Pharmaceuticals and Taiho Pharmaceutical sign cancer drug deal with Merck that could be worth $2.5billion

09 January 2020

The Cambridge Science Park company and its sister firm will receive an upfront payment of $20million.


An interview with Mene Pangalos on his knighthood, the new AstraZeneca HQ and changing mindsets

An interview with Mene Pangalos on his knighthood, the new AstraZeneca HQ and changing mindsets

An interview with Mene Pangalos on his knighthood, the new AstraZeneca HQ and changing mindsets

08 January 2020

‘I wasn’t particularly good at school,’ he admits.


Expedeon AG to rebrand as 4basebio and focus on DNA manufacture after Abcam concludes 120m euro deal

Expedeon AG to rebrand as 4basebio and focus on DNA manufacture after Abcam concludes 120m euro deal

Expedeon AG to rebrand as 4basebio and focus on DNA manufacture after Abcam concludes 120m euro deal

04 January 2020

An interview with CEO Dr Heikki Lanckriet.


Mission Therapeutics confirms potential Alzheimer’s and Parkinson’s targets with AbbVie

Mission Therapeutics confirms potential Alzheimer’s and Parkinson’s targets with AbbVie

Mission Therapeutics confirms potential Alzheimer’s and Parkinson’s targets with AbbVie

21 December 2019

Several enzymes have been identified under the collaboration.

4

Chinese Medical Systems to invest £25m by plugging into AstraZeneca and Cambridge Judge Business School life science networks

Chinese Medical Systems to invest £25m by plugging into AstraZeneca and Cambridge Judge Business School life science networks

Chinese Medical Systems to invest £25m by plugging into AstraZeneca and Cambridge Judge Business School life science networks

21 December 2019

Chinese Medical Systems will offer seed investment capital in five-year programme.


Martin Frost: Why I’m standing down as CEO of CMR Surgical - and Per Vegard Nerseth is the right man to succeed me

Martin Frost: Why I’m standing down as CEO of CMR Surgical - and Per Vegard Nerseth is the right man to succeed me

Martin Frost: Why I’m standing down as CEO of CMR Surgical - and Per Vegard Nerseth is the right man to succeed me

19 December 2019

He has led the robotics company from start-up to billion-dollar status and it is set to transform minimal access surgery.


Healx signs deal with Boehringer Ingelheim to aid fight against rare neurological diseases

Healx signs deal with Boehringer Ingelheim to aid fight against rare neurological diseases

Healx signs deal with Boehringer Ingelheim to aid fight against rare neurological diseases

16 December 2019

The Cambridge company will use its Healnet AI platform to help identify new indications.


BiologIC’s factory-in-a-box means faster, cheaper cures

BiologIC’s factory-in-a-box means faster, cheaper cures

BiologIC’s factory-in-a-box means faster, cheaper cures

29 November 2019

Coaching cells to revert to healthy activity is core of simplified process


Cycle Pharmaceuticals signs partnership with Catalent to develop its rare disease drugs

Cycle Pharmaceuticals signs partnership with Catalent to develop its rare disease drugs

Cycle Pharmaceuticals signs partnership with Catalent to develop its rare disease drugs

22 November 2019

Zydis technology will be applied to four of the Cambridge company’s products.


OKRA Technologies becomes Veeva partner to drive AI into life science decision-making

OKRA Technologies becomes Veeva partner to drive AI into life science decision-making

OKRA Technologies becomes Veeva partner to drive AI into life science decision-making

21 November 2019

The St John’s Innovation Park company will integrate its platform into Veeva CRM Suggestions


PredictImmune to launch study of PredictSURE IBD test in US with Crohn’s & Colitis Foundation

PredictImmune to launch study of PredictSURE IBD test in US with Crohn’s & Colitis Foundation

PredictImmune to launch study of PredictSURE IBD test in US with Crohn’s & Colitis Foundation

14 November 2019

PRECIOUS study follows successful launch of IBD prognostic test in UK and Ireland.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More